Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
The Lancet Oncology,  Clinical Article

Zhang L et al. – Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy.

Methods

  • Patients were aged 18 years or older, were of east Asian ethnic origin, had a life expectancy of more than 12 weeks, histologically or cytologically confirmed stage IIIb or IV NSCLC, a WHO performance status of 0—2, and had completed four cycles of first-line platinum-based doublet chemotherapy without disease progression or unacceptable toxic effects.
  • Between Sept 28, 2008 and Aug 11, 2009, 296 patients were randomly assigned 1:1 to receive either gefitinib (250 mg per day orally) or placebo (orally) within 3—6 weeks after chemotherapy until progression or unacceptable toxic effects.
  • Randomisation was done via an interactive web response system with computer-generated randomisation codes.
  • Our primary endpoint was progression-free survival assessed in the intention-to-treat population.

Results
  • Progression-free survival was significantly longer with gefitinib (n=148) than with placebo (148) (median progression-free survival 4·8 months [95% CI 3·2—8·5] vs 2·6 months [1·6—2·8]; hazard ratio [HR] 0·42, 95% CI 0·33—0·55; p<0·0001).
  • Adverse events occurred more frequently with gefitinib than with placebo; the most common adverse events of any grade were rash (73 [50%] of 147 in the gefitinib group vs 14 [9%] of 148 in the placebo group), diarrhoea (37 [25%] vs 13 [9%]), and alanine aminotransferase increase (31 [21%] vs 12 [8%]).
  • The most commonly reported grade 3 or 4 adverse event was alanine aminotransferase increase (3 [2%] of 147 in the gefitinib group, none of 148 in the placebo group).
  • Ten of 147 (7%) patients given gefitinib and five of 148 (3%) patients given placebo had serious adverse events.
  • Three deaths were thought to be related to treatment with gefitinib: one from interstitial lung disease; one from lung infection; and one from pneumonia.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 Commonly prescribed drug for lower back pain not effective University of Rochester Medical Center, December 12, 2014

2 New drug could make vaccines more effective in the elderly University of Oxford News, November 14, 2014

3 Widely used osteoporosis drugs may prevent breast, lung and colon cancers The Mount Sinai Hospital, December 3, 2014

4 Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells Journal of Pharmacology and Experimental Therapeutics, December 10, 2014    Clinical Article

5 Factors affecting time to maintenance dose in patients initiating warfarin Pharmacoepidemiology and Drug Safety, December 12, 2014    Clinical Article

6 New use for an old drug could impact cirrhosis patients Baylor Health Care System, November 6, 2014

7 Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II Noninferiority Study Clinical Infectious Diseases, December 1, 2014    Clinical Article

8 Effectiveness of azithromycin in aspiration pneumonia: A prospective observational study Full Text BMC Infectious Diseases, December 12, 2014    Free full text    Clinical Article

9 Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis Alimentary Pharmacology and Therapeutics, December 24, 2014    Clinical Article

10 Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial The Lancet Oncology, December 24, 2014    Clinical Article

11 Statins reverse learning disabilities caused by genetic disorder UCLA Health System, November 18, 2014

12 Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease Full Text Clinical and Experimental Gastroenterology, December 15, 2014    Free full text    Review Article

13 Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure Hypertension, November 24, 2014    Clinical Article

14 Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia Full Text JAMA, June 4, 2014    Free full text    Evidence Based Medicine    Clinical Article

15 UCLA researchers find that drug used for another disease slows progression of Parkinson's UCLA Health System, October 10, 2014

16 Treatment of gram - positive infections in critically ill patients Full Text BMC Infectious Diseases, December 12, 2014    Free full text    Clinical Article

17 A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists The American Journal of Cardiology, December 5, 2014    Evidence Based Medicine    Review Article

18 Interactions between herbs and antidiabetics: an overview of the mechanisms, evidence, importance, and management Full Text Archives of Pharmacal Research, December 9, 2014    Free full text    Review Article

19 Toughest breast cancer may have met its match Johns Hopkins Medicine, December 11, 2014

20 High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection Clinical Gastroenterology and Hepatology , November 24, 2014    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List